IGC Pharma

IGC Pharma Advancing Alzheimer's research through therapeutic innovation and AI.

Sharing research, education and resources for patients, caregivers and the Alzheimer’s community. About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

Changes in behavior during the late afternoon or evening can be challenging for both people living with Alzheimer's dise...
09/08/2026

Changes in behavior during the late afternoon or evening can be challenging for both people living with Alzheimer's disease and their caregivers.

Researchers continue to study why these changes occur and the factors that may contribute to them. Recognizing these patterns may help caregivers better understand what their loved one is experiencing and support informed conversations with healthcare professionals.

Connection doesn't always come through words.It can be found in listening to a favorite song, sharing a walk, preparing ...
09/06/2026

Connection doesn't always come through words.

It can be found in listening to a favorite song, sharing a walk, preparing a meal together, or simply spending time side by side. These everyday moments can bring comfort and strengthen the bond between caregivers and people living with Alzheimer's disease.

Looking for more practical caregiving guidance? Download Caring for a Loved One with Alzheimer's Disease: First-Hand Experiences, a free resource supported by IGC Pharma.

Download your copy:https://igcpharma.com/wp-content/uploads/2025/12/Alzheimers_Caregivers-English-_Version.pdf

Alzheimer's disease is a global challenge, but its impact is not experienced equally around the world.Research continues...
08/26/2026

Alzheimer's disease is a global challenge, but its impact is not experienced equally around the world.

Research continues to explore how geography, healthcare access, socioeconomic factors, and other regional differences may influence diagnosis, care, and long-term outcomes.

Understanding these patterns can help advance Alzheimer's research and support more equitable approaches to care.

Read the full article: https://igcpharma.com/alzheimers-across-borders-a-global-look-at-regional-patterns-and-drivers-of-alzheimers-disease/

Author: Timag Sherif and Meti Abdella, Former Clinical Trial Intake Navigators

08/11/2026

IGC Pharma is 8 patients away from completing enrollment in its Phase 2 CALMA trial.

With 160 participants randomized to date and 8 additional randomizations expected before enrollment closure, the Company is strengthening its regulatory, biostatistical, AI-enabled data science, and strategic pharmaceutical development capabilities to support clinical data review, AI-assisted data quality activities, regulatory preparedness for potential engagement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and strategic evaluation by potential pharmaceutical partners following completion of the Phase 2 CALMA trial.

The Company is preparing for patient follow-up, database lock, unblinding, and topline analysis as IGC-AD1 advances toward expected Phase 2 topline results in the fourth quarter of 2026.

Read the full press release: https://investor.igcpharma.com/igc-pharma-strengthens-regulatory-readiness-as-phase-2-calma-alzheimers-trial-approaches-enrollment-closure-and-q4-topline-readout/

Brain health is an active area of Alzheimer's research.While there is no guaranteed way to prevent Alzheimer's disease, ...
08/02/2026

Brain health is an active area of Alzheimer's research.

While there is no guaranteed way to prevent Alzheimer's disease, researchers continue to explore how lifestyle factors may influence brain health over time and contribute to healthy aging.

Understanding what current research suggests helps us make more informed conversations about brain health.

07/30/2026

Following the federal jury verdict in United States v. Andrew Left, IGC Pharma announced that it is evaluating potential civil remedies.

The Company is reviewing the federal indictment, the jury verdict, and related SEC materials, and is evaluating whether the public record supports potential claims to recover damages arising from the alleged 2018 short campaign and related conduct that affected the Company and its shareholders.

Read the full press release: https://finance.yahoo.com/healthcare/articles/igc-pharma-evaluates-potential-recovery-123000378.html

As the Alzheimer's Association International Conference 2026 comes to a close, we're proud of the contributions our AI t...
07/15/2026

As the Alzheimer's Association International Conference 2026 comes to a close, we're proud of the contributions our AI team shared with the global Alzheimer's research community.

Throughout the conference, the team presented AI-driven research and demonstrated aha™ (Agentic Harmonization Assistant) in connection with the Alzheimer's Disease Data Initiative (ADDI) AD Workbench ecosystem.

It was a valuable opportunity to exchange ideas, strengthen collaborations, and contribute to conversations advancing Alzheimer's research.

Thank you to everyone who connected with us in London.

Scientific progress is driven by collaboration, curiosity, and the exchange of ideas.This week, members of the IGC Pharm...
07/14/2026

Scientific progress is driven by collaboration, curiosity, and the exchange of ideas.

This week, members of the IGC Pharma AI team are attending the Alzheimer's Association International Conference 2026 in London, where they're presenting AI-driven research in Alzheimer's disease and collaborating with scientists from around the world.

We're proud to contribute to the global scientific community and to be part of the conversations and collaborations that help advance Alzheimer's research.

07/10/2026

IGC Pharma will present its artificial intelligence portfolio at the Alzheimer's Association International Conference (AAIC) 2026 in London.

The presentations, led by the Company's AI Team, highlight a broader AI strategy designed to address major bottlenecks in Alzheimer's development, from harmonizing fragmented datasets to identifying patients faster and supporting more targeted clinical workflows.

Read the full press release: https://finance.yahoo.com/technology/ai/articles/igc-pharma-showcase-ai-portfolio-130000772.html

Address

Potomac, MD

Telephone

+13019830998

Website

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to IGC Pharma:

Shortcuts

Featured

Share

Category